Today, we continue with our diversity series. In this article, please meet Andrea and Lucie. Andrea is our Clinical Research Associate from New Zealand, and Lucie is our Marketing & Sales Assistant from Czech Republic. Would you like to learn more about them?
Investment Press Release
hemotune makes a significant step forward: advancing into clinical trials after completing CHF 14 million Series B2 round
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Diversity Hemex Team
We welcome David to the team!
HEMEX contribution for preparing tomorrow's leaders!
Continue reading
Investment Press Release
Driving the future of non-surgical endometriosis diagnosis: Hera Biotech acquires Scailyte’s endometriosis diagnostic assets
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Hemex Team
Graphic Design Internship at HEMEX
Noémie is a student at FMS Muttenz. She completed a two-week internship at HEMEX focusing [...]
Continue reading
Hemex Team Press Release
HEMEX opens subsidiary in Belgium, expanding its presence in the EU
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
October is known as the worldwide awareness month of breast cancer. Previously, we have talked about how early detection and personalized cancer treatment plans are key factors in breast cancer control. The purpose of this year’s message is to focus on what can be done before? We’ll talk about some preventive measures which individuals can follow to take care of their well-being.
HEMEX is pleased to introduce you to the new talented minds and charismatic personalities on the team! Are you curious? Then keep reading, because today you will learn more about our office manager and executive assistant Serena and our junior sales associate Loïc.
Collaboration, Innovation, Press Release
Comms&Media service for startups powered by Benz Advisory, mediacrewgroup, and HEMEX
Benz Advisory, mediacrewgroup, and HEMEX join forces to support early-stage companies with strategic communications through a new service called Comms&Media. Targeted at early-stage businesses from all industries, it offers a unique, holistic approach to help companies develop and implement effective external and internal communications.
Every Start-up knows the importance of a great pitch. Today we want to give you some advice on how to find out the essential ingredients to bake a delicious pitch which investors will enjoy every single bite. More importantly, leave them craving for more!
Resistell has started the Performance Evaluation Study (PES) of its groundbreaking nanomotion technology at Lausanne University Hospital. At HEMEX, are very happy to be part of this project, as we will be monitoring the clinical trial over the next 12 months.
Inura Medical’s mission is to improve women’s health through the development of an urethral ovulum for the treatment of patients suffering from urinary bladder diseases. Their first pharmaceutical product is addressing an unmet medical need in overactive bladder (OAB).
HexagonFab, a spin-out from the University of Cambridge, has developed a novel approach for drug discovery and production process monitoring called the Bolt. This innovative device is an analytical lab instrument that provides convenient and affordable access to molecular binding analytics.
We’re thrilled to announce an exciting new partnership between HEMEX and YouEngineering, a software engineering company which aims to foster digital progress. Our latest partnership enables us to provide healthcare start-ups with a new range of digital packages to guarantee our clients the best results in mobile app, software development, and web design.
HEMEX is delighted to announce an exciting new partnership with Avanti Europe. The
Avanti Europe team is a specialist consultancy and expert knowledge provider. This
partnership will allow us to complete the range of products we provide to healthcare start-ups to ensure we continue offering excellent support within the life science industry.